World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 28 May 2018
Main ID:  EUCTR2011-005251-13-GR
Date of registration: 14/05/2012
Prospective Registration: Yes
Primary sponsor: Amgen Inc
Public title: A study to find out more about the effect of AMG 181 in people with moderate to severe ulcerative colitis
Scientific title: A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis
Date of first enrolment: 05/06/2012
Target sample size: 315
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005251-13
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: yes
Other trial design description: placebo-controlled period followed by open label period (see Protocol section 3.1)
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 5
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Australia Austria Belgium Canada Czech Republic Denmark Estonia France
Germany Greece Hungary Italy Latvia Netherlands Norway Poland
Switzerland United Kingdom United States
Contacts
Name: IHQ Medical Info - Clinical Trials   
Address:  Dammstrasse 23, P.O. Box 1557 CH-6300 Zug Switzerland
Telephone: N/A
Email: MedinfoInternational@amgen.com
Affiliation:  Amgen (EUROPE) GmbH
Name: IHQ Medical Info - Clinical Trials   
Address:  Dammstrasse 23, P.O. Box 1557 CH-6300 Zug Switzerland
Telephone: N/A
Email: MedinfoInternational@amgen.com
Affiliation:  Amgen (EUROPE) GmbH
Key inclusion & exclusion criteria
Inclusion criteria:
¦ Age 18 to 65 at screening (inclusive)
¦ Diagnosis of UC established = 3 months before baseline by clinical and endoscopic evidence and corroborated by a histopathology report
¦ Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with a rectosigmoidoscopy score = 2 prior to baseline
¦ Subjects can be receiving the following treatments:
• Azathioprine or 6 mercaptopurine if treatment initiated at least 12 weeks prior to baseline and if stable dosage for = 8 weeks prior to baseline
• Methotrexate up to 25 mg/week if stable dosage for = 8 weeks prior to baseline
• 5 aminosalicylates and/or oral prednisone or equivalent up to 20 mg/day, if stable dosage for = 2 weeks prior to baseline
¦ Neurological exam free of clinically significant, unexplained signs or symptoms in the opinion of the investigator at screening
¦ Subject has no known history of active tuberculosis
¦ Subject has a negative test for tuberculosis during screening
¦ Subject has provided informed consent

For full list of inclusion criteria, please refer to section 4.1 of the protocol
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 305
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion criteria:
Disease specific:
¦ Disease limited to the rectum (ie, within 10 cm of the anal verge)
¦ Toxic megacolon
¦ Crohn’s Disease
¦ History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC
¦ Stool positive for C. Difficile toxin at screening

Excluded Medications:
¦ Immunosuppressive therapy with either cyclosporine A, tacrolimus, or mycophenolate mofetil, within 1 month prior to baseline
¦ Prior exposure to anti TNF agents, within 2 months, or 5 times the respective elimination half life (whichever is longer) prior to baseline
¦ Any prior exposure to vedolizumab, rituximab, efalizumab, natalizumab
¦ Use of topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to baseline
¦ Use of intravenous corticosteroids within 2 weeks prior to screening and during screening

Laboratory Abnormalities:
¦ Abnormal laboratory results at screening:
•Liver tests: either aspartate aminotransferase (AST), alanine transaminase (ALT) or alkaline phosphatase (ALP) > 2.0 Upper Limit of Normal (ULN) OR total bilirubin (TBL) > 1.5 ULN (except for subjects with Gilbert Syndrome)
• White blood cell count < 3,000 cells/mm³(< 3 x 10^9/L in SI units)
•Hemoglobin < 10 g/dL

General:
¦ Female subject is not willing to use two highly effective methods of birth control during treatment and for = 7 months after the last dose of investigational product (except if = 2 years postmenopausal or surgically sterile)
¦ Subject is pregnant or breast feeding, or might become pregnant within 7 months after the last dose of investigational product

For full list of exclusion criteria, please refer to section 4.2 of the protocol


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Moderate to severe Ulcerative Colitis
MedDRA version: 14.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Intervention(s)

Product Name: AMG 181
Product Code: AMG 181
Pharmaceutical Form: Solution for injection
INN or Proposed INN: AMG 181
Current Sponsor code: AMG 181
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 70-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Primary Outcome(s)
Primary end point(s): Remission at week 8 defined by a total Mayo Score = 2 points, with no individual subscore > 1 point
Secondary Objective: Key Secondary Objectives:
- To evaluate the effects of AMG 181 on induction of response at week 8 as assessed by the total Mayo Score
- To evaluate the effects of AMG 181 on mucosal healing at week 8 as assessed by rectosigmoidoscopy

Other Secondary objective:
- To evaluate the effects of AMG 181 on sustained remission at both week 8 and week 24 as assessed by the total Mayo Score


Timepoint(s) of evaluation of this end point: at week 8
Main Objective: To evaluate the effect of AMG 181 on induction of remission in subjects with moderate to severe UC at week 8 as assessed by a total Mayo Score = 2 points, with no individual subscore > 1 point
Secondary Outcome(s)
Secondary end point(s): Key Secondary Endpoints
- Response at week 8 as defined by a decrease from baseline in the total Mayo Score of = 3 points and = 30%, with an accompanying decrease in the subscore for rectal bleeding of = 1 point or an absolute subscore for rectal bleeding of 0 or 1
- Mucosal healing at week 8 as defined by an absolute subscore for rectosigmoidoscopy of 0 or 1

Other Secondary Endpoints:
- Sustained remission at both week 8 and week 24
Timepoint(s) of evaluation of this end point: key secondary endpoints: at week 8
Other secondary endpoint (i.e. sustained remission): week 8 and week 24
Secondary ID(s)
20110166
Source(s) of Monetary Support
Amgen Inc
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history